Abstract 6326: Dose-Response Efficacy and Safety of the Aldosterone Synthase Inhibitor Baxdrostat in Resistant Hypertension: A Systematic Review and Network Meta-Analysis
Abstract
Background: Resistant hypertension (RH) is associated with increased cardiovascular morbidity and mortality, with limited treatment options due to adverse effects and suboptimal control. Aldosterone plays a central role in RH pathophysiology, making aldosterone synthase inhibition a promising therapeutic target. Baxdrostat, a selective CYP11B2 inhibitor, has demonstrated dose-dependent reductions in aldosterone and blood pressure. This study aimed to evaluate the efficacy and safety of baxdrostat across different doses in patients with RH. Research Question: Does braxdostat show a dose-dependent reduction in the SBP and DBP of patients with RH? Methods: This systematic review and network meta-analysis was conducted in accordance with the PRISMA-NMA guidelines and was prospectively registered with PROSPERO (CRD420261359149). A comprehensive search of PubMed, Cochrane CENTRAL, Embase, Scopus, and Web of Science was performed from inception to April 2026. Randomized, double-blind, placebo-controlled trials in adults with RH were included. A frequentist random-effects network meta-analysis using a graph-theoretical approach was performed to compare baxdrostat doses (0.5-2 mg), with treatment ranking based on P-scores. Heterogeneity and inconsistency were assessed using I 2 , τ 2 , and Q statistics. Results: Four randomized controlled trials comprising 1535 RH patients were included in our analysis. Baxdrostat demonstrated a dose-dependent reduction in seated systolic blood pressure (SBP), with significant decreases at 2 mg (mean difference [MD] –8.46 mmHg, 95% CI –12.00 to –4.92) and 1 mg (–5.89 mmHg, –9.83 to –1.94), while 0.5 mg was not significantly different from placebo. Reductions in 24 hour ambulatory SBP were consistent across effective doses. Seated diastolic blood pressure (DBP) reduction was significant only at 2 mg. All doses significantly reduced aldosterone levels, however, the highest reduction was seen with braxdostat 2 mg (-4.03, 95% CI: -5.29 to -2.77) for serum aldosterone and -187.40 for urinary aldosterone. This was accompanied by compensatory increases in the urinary renin. Higher doses (1 mg and 2 mg) were associated with an increased risk of overall adverse events (1.21, 95% CI: 1.03 to 1.43, and 1.17, 95% CI: 1.01 to 1.36, respectively), and hyperkalemia (4.51, 95% CI: 1.73 to 11.70); baxdrostat 0.5 mg demonstrated the safest outcomes, however, it ranked first in causing hyponatremia and hypotension. There was no significant increase in serious adverse events compared with placebo. Conclusion: Baxdrostat is an effective and generally well-tolerated therapy for resistant hypertension, demonstrating dose-dependent blood pressure and aldosterone reductions. Its upstream mechanism offers a novel alternative to mineralocorticoid receptor antagonists. Larger and long-term studies are warranted to confirm its clinical role.